Production of recombinant protein therapeutics in cultivated mammalian cells
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Cultivated mammalian cells have become the dominant system for the production of recombinant proteins for clinical applications because of their capacity for proper protein folding, assembly and post-translational modification. Thus, the quality and efficacy of a protein can be superior when expressed in mammalian cells versus other hosts such as bacteria, plants and yeast. Recently, the productivity of mammalian cells cultivated in bioreactors has reached the gram per liter range in a number of cases, a more than 100-fold yield improvement over titers seen for similar processes in the mid-1980s. This increase in volumetric productivity has resulted mainly from improvements in media composition and process control. Opportunities still exist for improving mammalian cell systems through further advancements in production systems as well as through vector and host cell engineering.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advances in cell engineering, process control, and media composition are credited with improving the volumetric yield of cell culture bioprocesses, making biopharmaceutical manufacturing more cost-effective and practical [8].”
From The role of Raman spectroscopy in biopharmaceuticals from development to manufacturing (2022) · cites this paper as [8]
In the citing paper
“Chinese hamster ovary (CHO) cells are one of the main cell lines used in the production of recombinant therapeutics (Wurm, 2004; see Grillberger et al., 2009 for examples of proteins produced in CHO cells).”
From Virus susceptibility of Chinese hamster ovary (CHO) cells and detection of viral contaminations by adventitious agent testing (2010) · cites this paper as Wurm, 2004
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451 · cited 1×
“In 1973, Graham and van der Eb showed that exposing cells to nanoparticles of DNA and calcium phosphate makes possible DNA transfer into cultivated mammalian cell”
BackgroundEpigenetic Codes for Heterochromatin Formation and Silencing
Richards, E. J., & Elgin, S. C. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00644-x · Cited by 871
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
How introns influence and enhance eukaryotic gene expression
Le Hir, H., Nott, A., & Moore, M. J. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00052-5 · Cited by 734
Bebbington, C. R., Renner, G., Thomson, S., King, D., Abrams, D., & Yarranton, G. T. (1992) · Nature Biotechnology · doi:10.1038/nbt0292-169 · Cited by 462 · cited 1×
“At a concentration of 10–100 μM MSX, resistant clones can be identified in selected NS0 cell populations that have amplified the transgene complex containing the GS gene and the desired gene(s) of interes”
BackgroundGenetic and physical linkage of exogenous sequences in transformed cells
Perucho, M., Hanahan, D., & Wigler, M. (1980) · Cell · doi:10.1016/0092-8674(80)90178-6 · Cited by 455 · cited 1×
“Nuclear ligases assure the covalent joining of individual plasmid DNA molecule”
BackgroundExpression of recombinant plasmids in mammalian cells Is enhanced by sodium butyrate
Gorman, C. M., Howard, B. H., & Reeves, R. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.21.7631 · Cited by 367 · cited 1×
“Another way to inhibit silencing is to block deacetylation of histones using butyrat”
BackgroundSilencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9
Mutskov, V., & Felsenfeld, G. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600013 · Cited by 296
Kim, S. J., Kim, N. S., Ryu, C. J., Hong, H. J., & Lee, G. M. (1998) · Biotechnology and Bioengineering · doi:10.1002/(sici)1097-0290(19980405)58:1<73::aid-bit8>3.0.co;2-r · Cited by 220 · cited 1×
“Thus, it might be advantageous to omit selective drugs once promising clonal cell lines have been identifie”
BackgroundLarge-scale transient expression in mammalian cells for recombinant protein production
Wurm, F., & Bernard, A. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)80027-5 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Gorman, C.M., Howard, B.H. & Reeves, R. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 11, 7631–7648 (1983). · DOI · Paper page
Cited by
Items 701–800 of 1,007
Abbott, W. M., Middleton, B. J., Kartberg, F., Claesson, J., Roth, R. G., & Fisher, D. I. (2015) · Protein Expression and Purification · doi:10.1016/j.pep.2015.08.016 · Cited by 30
New frontiers in cell line development: challenges for biosimilars
Hou, J. J. C., Codamo, J., Pilbrough, W., Hughes, B. S., Gray, P. P., & Munro, T. P. (2011) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.2574 · Cited by 30
Kerr, R. A., Keire, D. A., & Ye, H. (2019) · mAbs · doi:10.1080/19420862.2019.1599632 · Cited by 30
Trimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens
Pino, P., Kint, J., Kiseljak, D., Agnolon, V., Corradin, G., Kajava, A. V., Rovero, P., Dijkman, R., den Hartog, G., McLellan, J. S., et al. (2020) · Processes · doi:10.3390/pr8121539 · Cited by 29
Self-citationHarreither, E., Hackl, M., Pichler, J., Shridhar, S., Auer, N., Łabaj, P. P., Scheideler, M., Karbiener, M., Grillari, J., Kreil, D. P., et al. (2015) · Biotechnology Journal · doi:10.1002/biot.201400857 · Cited by 34
“Due to improvements in bioprocess technology, feeds, and media composition, the final titers and process yields have significantly increased in the meantime, with titers of 5 g/L routinely reached [2, 3].”
BackgroundNoguchi, C., Araki, Y., Miki, D., & Shimizu, N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052990 · Cited by 31
“Because the production of protein pharmaceuticals, including cytokines and humanized antibodies, depends on the use of cultured mammalian cells, a robust method for the production of large amounts of recombinant protein in mammalian cells has become increasingly important (reviewed in [7]).”
MethodSingle-Batch Production of Recombinant Human Polyclonal Antibodies
Nielsen, L. S., Baer, A. S., Müller, C. R., Gregersen, K., Mønster, N. T., Rasmussen, S. K., Weilguny, D., & Tolstrup, A. B. (2010) · Molecular Biotechnology · doi:10.1007/s12033-010-9270-9 · Cited by 28
“Methods for development and manufacture of recombinant monoclonal antibodies are well established [9–11].”
木田, 晶., Iijima, M., Niimi, T., Maturana, A. D., Yoshimoto, N., & Kuroda, S. (2013) · Analytical Chemistry · doi:10.1021/ac303067k · Cited by 29
Increasing batch-to-batch reproducibility of CHO cultures by robust open-loop control
Aehle, M., Kuprijanov, A., Schaepe, S., Simutis, R., & Lübbert, A. (2010) · Cytotechnology · doi:10.1007/s10616-010-9320-y · Cited by 28
“…of Automation and Control Systems, Kaunas University of Technology, Studentu g. 48, 3028 Kaunas, Lithuania From their history, most animal cell-based production processes are extended batch cultures where medium components are added in small discrete portions or semi-continuously (Wurm 2004).”
BackgroundYoshimura, H., Sekine, S., Adachi, H., Uematsu, Y., Mitani, A., Futaki, N., & Shimizu, N. (2011) · Protein Expression and Purification · doi:10.1016/j.pep.2011.05.009 · Cited by 28
“To improve this low productivity, some gene amplification methods have been developed [2].”
MethodDharshanan, S., Chong, H., Hung, C. S., Zamrod, Z., & Kamal, N. (2011) · Electronic Journal of Biotechnology · doi:10.2225/vol14-issue2-fulltext-7 · Cited by 28
Wippermann, A., Klausing, S., Rupp, O., Albaum, S. P., Büntemeyer, H., Noll, T., & Hoffrogge, R. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-5282-2 · Cited by 29
“In many cases such transgenes become rapidly silenced even if they are integrated into active euchromatin (Wurm 2004).”
BackgroundOverexpression of YY1 increases the protein production in mammalian cells
Tastanova, A., Schulz, A., Folcher, M., Tolstrup, A. B., Puklowski, A., Kaufmann, H., & Fussenegger, M. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.12.005 · Cited by 33
Zhang, L., Zhang, W., Wang, C., Liu, J., Deng, X., Liu, X., Li, F., & Tan, W. (2016) · Bioresources and Bioprocessing · doi:10.1186/s40643-015-0072-6 · Cited by 29
“Mammalian cell culture has been used to produce various recombinant proteins for therapeutic applications (Wurm 2004).”
BackgroundInfluentialOrellana, C. A., Marcellin, E., Gray, P. P., & Nielsen, L. K. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26316 · Cited by 31
Maximum entropy and population heterogeneity in continuous cell cultures
Fernández-de-Cossio-Díaz, J., & Mulet, R. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006823 · Cited by 31
“Recombinant protein production requires suitable cell hosts and culture conditions [1].”
BackgroundOn-chip manufacturing of synthetic proteins for point-of-care therapeutics
Murphy, T. W., Sheng, J., Naler, L. B., Feng, X., & Lu, C. (2019) · Microsystems & Nanoengineering · doi:10.1038/s41378-019-0051-8 · Cited by 28
Lin, J.-Y., Ke, Y., Lai, J.-S., & Ho, T. (2015) · Phytomedicine · doi:10.1016/j.phymed.2015.06.012 · Cited by 28
Hartman, T. E., Sar, N., Genereux, K., Barritt, D. S., He, Y., Burky, J. E., Wesson, M. C., Tso, J. Y., Tsurushita, N., Zhou, W., et al. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21099 · Cited by 28
Sánchez-Bustamante, C. D., Kelm, J. M., Guarino, B., & Fussenegger, M. (2005) · Biotechnology and Bioengineering · doi:10.1002/bit.20679 · Cited by 29
Aeration, Mixing, and Hydrodynamics, Animal Cell Bioreactors
Godoy‐Silva, R. D., Berdugo, C., & Chalmers, J. J. (2010) · Wiley eBooks · doi:10.1002/9780470054581.eib010 · Cited by 32
Kozma, B., Salgó, A., & Gergely, S. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.06.005 · Cited by 27
“However, the production of these molecules equires mammalian cell cultivation processes to reach the desired olecular composition, which is a key factor to ensure the desired herapeutic effectiveness and to avoid undesirable therapeutic side ffects of the mAb [3].”
BackgroundProteins improving recombinant antibody production in mammalian cells
Nishimiya, D. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-5427-3 · Cited by 29
“Mammalian cells such as NS0 murine myeloma cells and Chinese hamster ovary (CHO) cells are predominantly utilized to produce mAbs, since they can generate correctly folded and glycosylated proteins (Wurm 2004; Li et al. 2010).”
BackgroundA totally recombinant human fibrin sealant
Carlson, M. A., Calcaterra, J., Johanning, J. M., Pipinos, I. I., Cordes, C. M., & Velander, W. H. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.09.039 · Cited by 29
“The complexity of FI and FIIa necessitates that recombinant versions of these proteins be made in animal cells [22].”
BackgroundFrom chemostats to high‐density perfusion: the progression of continuous mammalian cell cultivation
Wong, H. E., Chen, C., Le, H., & Goudar, C. T. (2021) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.6841 · Cited by 29
Sreter, J. A., Foxall, T. L., & Varga, K. (2022) · Biomolecules · doi:10.3390/biom12050669 · Cited by 27
Calcaterra, J., Cott, K. E. V., Butler, S. P., Gil, G. C., Germano, M., van Veen, H. A., Nelson, K., Forsberg, E. J., Carlson, M. A., & Velander, W. H. (2012) · Biomacromolecules · doi:10.1021/bm301579p · Cited by 31
Generation of pluripotent stem cells via protein transduction
Li, X., Zhang, P., Wei, C., & Zhang, Y. (2014) · The International Journal of Developmental Biology · doi:10.1387/ijdb.140007xl · Cited by 28
Mason, M., Sweeney, B., Cain, K., Stephens, P. E., & Sharfstein, S. T. (2014) · Antibodies · doi:10.3390/antib3030253 · Cited by 32
“Development of novel expression vectors, robust cell-culture media, stringent cell-line selection strategies, and efficient production processes have pushed maximum achievable titers well into the g/L range [2,3].”
BackgroundAllergic Aspergillosis and the Antigens of Aspergillus fumigatus
Singh, B., Singh, S., Asif, A. R., Oellerich, M., & Sharma, G. L. (2014) · Current Protein and Peptide Science · doi:10.2174/1389203715666140512120605 · Cited by 28
“It was reported that the stably transected Chinese hamster ovary cells expressed recombinant antibodies up to a level of a few grams per liter [149, 147].”
BackgroundStrategies for Engineering Protein N-Glycosylation Pathways in Mammalian Cells
Wang, Q., Stuczynski, M. C., Gao, Y., & Betenbaugh, M. J. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2760-9_20 · Cited by 31
Scarcelli, J. J., Hone, M., Beal, K. M., Ortega, A., Figueroa, B., Starkey, J. A., & Anderson, K. (2018) · Biotechnology Progress · doi:10.1002/btpr.2646 · Cited by 28
“The general procedure to generate a CHO cell line expressing a recombinant therapeutic is well-established: DNA expression plasmid(s) encoding the transgene(s) of the biologic as well as a selectable marker is transfected into a host cell.(3) The resulting culture is a pool of cells that are typically the product of m…”
MethodLin, H., Du, Q., Li, Q., Wang, O., Wang, Z., Sahu, N., Elowsky, C. G., Liu, K., Zhang, C., Chung, S., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.07.001 · Cited by 29
“For instance, hPSCs typically expand 4-fold in 4 days to yield around 1.0 3 106 to 2.0 3 106 cells/mL, which occupy 0.4% of the bioreactor volume (Lei et al., 2014; Serra et al., 2012; Steiner et al., 2010; Wurm, 2004).”
BackgroundInfluentialMitochondrial membrane potential identifies cells with high recombinant protein productivity
Chakrabarti, L., Mathew, A., Li, L., Han, S., Klover, J., Albanetti, T., & Hawley‐Nelson, P. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.10.007 · Cited by 27
Fu, Q., Si, Y., Liu, L., Yu, J., & Ding, B. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2019.07.065 · Cited by 27
Automation of Dead End Filtration: An Enabler for Continuous Processing of Biotherapeutics
Thakur, G., Hebbi, V., Parida, S., & Rathore, A. S. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00758 · Cited by 27
“High cell density is now commonly achieved in both mammalian and microbial processes, and therefore Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 1 July 2020 | Volume 8 | Article 758 primary recovery of cells can be a significant challenge (Wurm, 2004; Aldor et al., 2005).”
BackgroundManufacturing antibodies in the plant cell
Orzáez, D., Granell, A., & Blázquez, M. A. (2009) · Biotechnology Journal · doi:10.1002/biot.200900223 · Cited by 31
“human glycosylation profiles [6]; CHO cells have multiplied their yields, reaching g/L levels [7]; alternative animal systems as chicken eggs have arisen [8], and baculovirus-”
BackgroundPlatforms for Recombinant Therapeutic Glycoprotein Production
Mizukami, A., Caron, A. L., Picanço‐Castro, V., & Swiech, K. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7312-5_1 · Cited by 31
“and 5 g/L for an extended-batch culture process lasting up to three weeks have already been reported [58].”
BackgroundAdvancements in CHO metabolomics: techniques, current state and evolving methodologies
Singh, R., Fatima, E., Thakur, L., Singh, S., Ratan, C., & Kumar, N. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1347138 · Cited by 29
“…fast to achieve high-density in protein-free and chemically de fi ned culture media, perform human-like post-translational modi fi cations, appropriate protein folding, high productivity and low susceptibility to human viral infections (Wurm, 2004; Lalonde and Durocher, 2017; Singh et al., 2023).”
BackgroundZhang, S., Bartkowiak, L., Nabiswa, B., Mishra, P., Fann, J., Ouellette, D., Correia, I., Regier, D. A., & Liu, J. (2015) · Biotechnology Progress · doi:10.1002/btpr.2119 · Cited by 27
Traeger, A., Synatschke, C. V., Pergushov, D. V., Jérôme, V., Müller, A. H. E., & Freitag, R. (2011) · Langmuir · doi:10.1021/la201803c · Cited by 26
An efficient route to bispecific antibody production using single-reactor mammalian co-culture
Shatz-Binder, W., Ng, D., Dutina, G., Wong, A. W., Dunshee, D. R., Sonoda, J., Shen, A. Y., & Scheer, J. M. (2016) · mAbs · doi:10.1080/19420862.2016.1234569 · Cited by 28
“In contrast, early stage mammalian host antibody production generally relies on transient expression, where HC and LC genes are expressed non-chromosomally.(15,24) When CHO cells are used, it is common for cells to be simultaneously cotransfected with separate HC and LC DNA.”
BackgroundObaidi, I., Mota, L. M., Quigley, A., & Butler, M. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11244-8 · Cited by 28
“The gradual incremental improvement of media composition over time has accounted for significant productivity increases in commercial bioproduction processes (Wurm 2004).”
BackgroundPape, F. L., Bossard, M., Dutheil, D., Rousselot, M., Polard, V., Férec, C., Leize‐Zal, E., Delépine, P., & Zal, F. (2015) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2015.1029632 · Cited by 28
Bile acid-controlled transgene expression in mammalian cells and mice
Roessger, K., Hamri, G. C., & Fussenegger, M. (2013) · Metabolic Engineering · doi:10.1016/j.ymben.2013.11.003 · Cited by 27
“…et al., 2004; Friedland et al., 2009), discovering new drugs and manufacturing biopharmaceuticals (Sharpless and Depinho, 2006; Weber et al., 2008; Wurm, 2004; Ulmer et al., 2006; Weber and Fussenegger, 2007; Gitzinger et al., 2009b) as well as designing specialized biomaterials (Greber and…”
BackgroundPohlscheidt, M., Langer, U., Minuth, T., Bödeker, B. G. D., Apeler, H., Hörlein, H.-D., Paulsen, D., Rübsamen‐Waigmann, H., Henzler, H., & Reichl, U. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.01.032 · Cited by 26
Böhm-Hofstätter, H., Tschernutter, M., & Kunert, R. (2010) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-010-2580-9 · Cited by 31
“, glycosylation) closer than bacterial or yeast cell lines (Wurm 2004).”
Using Molecular Markers to Characterize Productivity in Chinese Hamster Ovary Cell Lines
Edros, R. Z., McDonnell, S., & Al‐Rubeai, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075935 · Cited by 29
“Having the slowest growth rates, CL 47[1] exhibited the highest total antibody, followed by CL 76[2], CL 38[5], CL 150[3], CL 164[4] and CL 160[6].”
BackgroundInfluentialManufacture of recombinant polyclonal antibodies
Rasmussen, S. K., Rasmussen, L. K., Weilguny, D., & Tolstrup, A. B. (2007) · Biotechnology Letters · doi:10.1007/s10529-007-9331-8 · Cited by 26
“However, the individual PALS may have different properties with respect to e.g. glucose consumption, lactate production and sensitivity towards stress factors (Wurm 2004).”
BackgroundLi, H., Chen, K., Wang, Z., Li, D., Lin, J., Yu, C., Fang, Y., Wang, X., Huang, L., Jiang, C., et al. (2015) · Molecular BioSystems · doi:10.1039/c5mb00627a · Cited by 26
Badri, M. A., Rivard, D., Coenen, K., Vaillancourt, L., Goulet, C., & Michaud, D. (2008) · PROTEOMICS · doi:10.1002/pmic.200700233 · Cited by 28
“Several biological systems have been devised for the heterologous expression of proteins, ranging from thewidely usedbacteriumEscherichia coli for structurally simple proteins [2] to eukaryotic hosts such as yeasts, mammalian cells, animals, and plants for proteins depending on complex PTMs to show adequate activity o…”
BackgroundChumsae, C. M., Hossler, P., Raharimampionona, H., Zhou, Y., McDermott, S., Racicot, C., Radziejewski, C. H., & Zhou, Z. S. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b00801 · Cited by 29
Identifying and retargeting transcriptional hot spots in the human genome
Cheng, J. K., Lewis, A. M., Kim, D. S., Dyess, T. J., & Alper, H. S. (2016) · Biotechnology Journal · doi:10.1002/biot.201600015 · Cited by 29
“The importance of integration sites has been well established [8, 9, 11, 24, 25], however, limited information is available about desirable sites with only a few characterized in particular cell types with interesting characteristics [26, 27].”
BackgroundCell Culture Media in Bioprocessing
Whitford, W. G., Lundgren, M., & Fairbank, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-100623-8.00008-6 · Cited by 25
DNA retention on depth filters
Khanal, O., Xu, X., Singh, N., Traylor, S. J., Huang, C., Ghose, S., Li, Z. J., & Lenhoff, A. M. (2018) · Journal of Membrane Science · doi:10.1016/j.memsci.2018.10.058 · Cited by 26
“factor because the continuous cell lines in question were immortalized, leading to a requirement that DNA be reduced to exceptionally low levels [2,3].”
BackgroundHeterogeneity Studies of Mammalian Cells for Bioproduction: From Tools to Application
Schmitz, J., Noll, T., & Grünberger, A. (2019) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.11.007 · Cited by 28
Smith, S. N., Schubert, R., Simic, B., Brücher, D., Schmid, M., Kirk, N., Freitag, P. C., Gradinaru, V., & Plückthun, A. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2017925118 · Cited by 26
“Notably, these values are in the range of antibody production yields from Chinese hamster ovary (CHO) cells, which yield ∼20 pg per cell per day (25).”
BackgroundIllanes, A. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8361-7_2 · Cited by 26
Scale-Up of Protein Purification: Downstream Processing Issues
Milne, J. J. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-913-0_5 · Cited by 26
Bioreactors for Mammalian Cells: General Overview
Eibl, D., & Eibl, R. (2009) · Principles and practice · doi:10.1007/978-3-540-68182-3_3 · Cited by 25
“● Scale down bioreactors, representing small-scale laboratory bioreactors for cell line screening, medium optimization, and basic studies, which operate with microwell plates, tubes, spinner flasks, or shake flasks and allow online measurement and regulation of relevant process parameters (DeJesus et al. 2004; Kumar e…”
BackgroundInfluentialRecombinant DNA expression products for human therapeutic use
Bhopale, G. M., & Nanda, R. K. (2005) · Cited by 31
Bioreactors, Cell Culture, Commercial Production
Zhou, T.-C., Zhou, W.-W., Hu, W.-W., & Zhong, J.-J. (2010) · Wiley eBooks · doi:10.1002/9780470054581.eib637 · Cited by 22
Glycosylation pattern of humanized IgG-like bispecific antibody produced by recombinant CHO cells
Kim, W.-D., Tokunaga, M., Ozaki, H., Ishibashi, T., Honda, K., Kajiura, H., Fujiyama, K., Asano, R., Kumagai, I., Ōmasa, T., et al. (2009) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-009-2152-z · Cited by 27
“With several monoclonal antibody products currently on the market and more than 100 under clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals ( Wurm 2004; Butler 2005; Holliger and Hudson 2005).”
BackgroundSoh, H. S., Chung, H. Y., Lee, H. H., Ajjappala, H., Jang, K., Park, J.-H., Sim, J.-S., Lee, G. Y., Lee, H. J., Han, Y. H., et al. (2015) · SpringerPlus · doi:10.1186/s40064-015-0847-4 · Cited by 25
“The production of recombinant proteins, such as biopharmaceuticals and vaccines, is commonly performed using bacterial, yeast and mammalian cell expression systems (Wurm 2004; Sue et al. 2005; Terpe 2006; Chen 2012; Mattanovich et al. 2012; Tingfeng et al. 2013).”
BackgroundBio-Orthogonal Mediated Nucleic Acid Transfection of Cells via Cell Surface Engineering
O’Brien, P. J., Elahipanah, S., Rogozhnikov, D., & Yousaf, M. N. (2017) · ACS Central Science · doi:10.1021/acscentsci.7b00132 · Cited by 28
Junghans, L., Teleki, A., Wijaya, A. W., Becker, M., Schweikert, M., & Takors, R. (2019) · Metabolic Engineering · doi:10.1016/j.ymben.2019.02.005 · Cited by 25
Torres, M., Hussain, H., & Dickson, A. J. (2022) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2022.2047004 · Cited by 25
“17 billion in 2020) [1], biopharmaceuticals have been revolutionary therapeutic tools that changed the paradigm of how we treat complex life-threatening diseases, such as cancer or autoimmune disorders [2].”
BackgroundRecombinant mucin biotechnology and engineering
Park, S., Kuo, J. C., Reesink, H. L., & Paszek, M. J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114618 · Cited by 27
Stem cell-based ischemic stroke therapy: Novel modifications and clinical challenges
Sun, Y., Jiang, X., & Gao, J. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100867 · Cited by 32
“This technique modulates gene expression by transferring specific genes into cells, ultimately enhancing or inhibiting specific functions [122] .”
BackgroundNorouzian, D., Ahangari, Madadkar, Khanahmad, Roohvand, Aghasadeghi, Ardestani, M. S., Inanlou, D. N., & Hedayati (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s19081 · Cited by 25
A novel, high stringency selection system allows screening of few clones for high protein expression
VANBLOKLAND, H., Kwaks, T., Sewalt, R. G. A. B., Verhees, J., Klaren, V. N. A., Siersma, T. K., Korse, J. W. M., Teunissen, N. C., Botschuijver, S., VANMER, C., et al. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.09.023 · Cited by 32
Bian, Q., & Belmont, A. S. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq178 · Cited by 29
Cole, H., Demont, A., & Marison, I. W. (2015) · Processes · doi:10.3390/pr3020384 · Cited by 26
“Mammalian cells are commonly used to produce biopharmaceuticals as they are capable of correct glycosylation and other post-translational modifications of therapeutic proteins [1–4].”
BackgroundOptimization of conditions for gene delivery system based on PEI
Cheraghi, R., Alipour, M., Nazari, M., & Hosseinkhani, S. (2017) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.22038/nmj.2017.8047 · Cited by 25
Henry, M. A., Power, M., Kaushik, P., Coleman, O., CLYNES, M. M., & Meleady, P. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00868 · Cited by 29
Roy, G., Zhang, S., Li, L., Higham, E. M., Wu, H., Marelli, M., & Bowen, M. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183694 · Cited by 31
Affinity maturation and characterization of the ofatumumab monoclonal antibody
Payandeh, Z., Rajabibazl, M., Mortazavi, Y., Rahimpour, A., Taromchi, A. H., & Dastmalchi, S. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27457 · Cited by 25
“These include the ability of suspension culture in high density, genetic modification so that entrance of foreign DNA and expression of foreign protein in high levels are achievable, glycosylation capabilities for proteins, required posttranslational modifications for biological activity of protein, the safety of the…”
BackgroundMartínez‐Monge, I., Comas, P., Triquell, J., Lecina, M., Casablancas, A., & Cairó, J. J. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9388-4 · Cited by 25
An arginase-based system for selection of transfected CHO cells without the use of toxic chemicals
Roca, B. C., Lao, N. T., Barron, N., Doolan, P., & CLYNES, M. M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011162 · Cited by 27
“Similar to the findings reported here, a lack of arginase activity and subsequent decreases in cellular growth has been previously reported with CHO cells cultured in absence of putrescine, with cellular death observed after 8 –14 days (18, 19) because of the intracellular depletion of the secondary polyamines spermin…”
BackgroundResultAltamirano, C., Illanes, A., Canessa, R., & Becerra, S. (2006) · Electronic Journal of Biotechnology · doi:10.2225/vol9-issue1-fulltext-8 · Cited by 25
Evolution of a comprehensive, orthogonal approach to sequence variant analysis for biotherapeutics
Lin, T. J., Beal, K. M., Brown, P. W., DeGruttola, H. S., Ly, M., Wang, W., Chu, C. H., Dufield, R. L., Casperson, G. F., Carroll, J. A., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1531965 · Cited by 25
“Unlike microbial hosts, mammalian systems synthesize biologically active protein therapeutics by imparting proper protein folding and post-translational modifications.(5) In pursuit of ever-increasing titers to meet high worldwide demand and offset costs of medicines, bioprocess technologies and approaches for cell li…”
BackgroundRoy, G., Miró-Quesada, G., Li, Z., Martin, T., Zhu, J., Wu, H., Marelli, M., & Bowen, M. A. (2017) · Journal of Immunological Methods · doi:10.1016/j.jim.2017.08.012 · Cited by 26
“This process is labor intensive and may take months to complete (de la Cruz Edmonds et al., 2006; Fussenegger et al., 1999; Wurm, 2004).”
BackgroundMethodByun, H., Park, J., Kim, S. C., & Ahn, J. H. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.786749 · Cited by 24
Bioproduced Proteins On Demand (Bio-POD) in hydrogels using Pichia pastoris
Yuan, S., Brooks, S. M., Nguyen, A. W., Lin, W.-L., Johnston, T. G., Maynard, J. A., Nelson, A., & Alper, H. S. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.01.019 · Cited by 25
Alomran, N., Blundell, P. A., Alsolaiss, J., Crittenden, E., Ainsworth, S., Dawson, C. A., Edge, R. J., Hall, S. R., Harrison, R. A., Wilkinson, M. C., et al. (2022) · Toxins · doi:10.3390/toxins14070443 · Cited by 26
Srila, W., Baumann, M., Riedl, M., Rangnoi, K., Borth, N., & Yamabhai, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-37288-6 · Cited by 26
Mammalian Stable Expression of Biotherapeutics
Jostock, T., & Knopf, H. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-921-1_15 · Cited by 28
Growth of BY‐2 Suspension Cells and Plantibody Production in Single‐Use Bioreactors
Raven, N. P. G., Schillberg, S., Kirchhoff, J., Brändli, J., Imseng, N., & Eibl, R. (2010) · Wiley eBooks · doi:10.1002/9780470909997.ch21 · Cited by 24
RNA interference of cofilin in Chinese hamster ovary cells improves recombinant protein productivity
Hammond, S., & Lee, K. H. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23322 · Cited by 29
“Chinese hamster ovary (CHO) cells are the most commonly used mammalian cell line for production of biopharmaceutical proteins that require proper folding and glycosylation for full activity (Wurm, 2004).”
BackgroundAugusto, E. F. P., Moraes, Â. M., Piccoli, R. A. M., Barral, M. F., Suazo, C. A. T., Tonso, A., & Pereira, C. A. D. B. (2009) · Biologicals · doi:10.1016/j.biologicals.2009.07.005 · Cited by 24
Jossé, L., Smales, C. M., & Tuite, M. F. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22572 · Cited by 27
“3, February 15, 2010 that can be employed as bio-pharmaceutical agents (Wurm, 2004).”
BackgroundTransient Production of scFv-Fc Fusion Proteins in Mammalian Cells
Schirrmann, T., & Büssow, K. (2010) · Springer eBooks · doi:10.1007/978-3-642-01147-4_30 · Cited by 24
“In addition the still continuing progress of the mammalian cell culture technology has already reached IgG production levels of more than 5 g/L in the industry (Wurm 2004).”
BackgroundCell Immobilization: Fundamentals, Technologies, and Applications
Ge, X., Yang, L., & Xu, J. (2016) · Wiley eBooks · doi:10.1002/9783527807833.ch7 · Cited by 30
Lo, C., Greben, A. W., & Chen, B. E. (2017) · BioTechniques · doi:10.2144/000114534 · Cited by 26
Mosser, M., Kapel, R., Chevalot, I., Olmos, É., Marc, I., Marc, A., & Oriol, E. (2015) · Biotechnology Progress · doi:10.1002/btpr.2110 · Cited by 26
“Mammalian cells, and especially Chinese Hamster Ovary (CHO) cells, are currently the main expression system used to produce monoclonal antibodies.(1) At first, these cells were grown in animal-derived sera media to promote cell growth and protein production.”
BackgroundGaillet, B., Gilbert, R., Amziani, R., Guilbault, C., Gadoury, C., Caron, A. W., Mullick, A., Garnier, A., & Massie, B. (2007) · Biotechnology Progress · doi:10.1021/bp060187j · Cited by 31
Elucidation of metabolism in hybridoma cells grown in fed‐batch culture by genome‐scale modeling
Selvarasu, S., Wong, V. V. T., Karimi, I. A., & Lee, D. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.22186 · Cited by 24
“The increasing market demand for such commercially valuable compounds can be satisfied by developing high-yielding mammalian cell culture processes (Wurm, 2004).”
Vaccinating with the genome: a Sisyphean task?
Coppel, R. L. (2009) · Trends in Parasitology · doi:10.1016/j.pt.2009.02.006 · Cited by 25
Shimizu, N., Hanada, N., Utani, K., & Sekiguchi, N. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21313 · Cited by 24
Metcalf, K. J., Finnerty, C. T. K., Azam, A., Valdivia, E., & Tullman‐Ercek, D. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.01330-14 · Cited by 25
“Moreover, secretion provides an initial purification event and thus may simplify downstream sample purification (5, 6, 43).”
Background
Metadata
- Authors
- Wurm, F. M.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Corresponding author
- Wurm, Florian M
- ORCID
- Wurm, Florian M
- Venue
- Nature Biotechnology
- Published
- 2004-11
- Volume
- 22
- Issue
- 11
- Pages
- 1393-1398
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2118540273
- Cited by
- 2,032
- References
- 52
- Citations by year
- 2026: 52 · 2025: 51 · 2024: 66 · 2023: 66 · 2022: 64 · 2021: 77 · 2020: 89 · 2019: 114 · 2018: 162 · 2017: 118 · 2016: 95 · 2015: 135 · 2014: 108 · 2013: 145 · 2012: 111
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
- Keywords
- recombinant therapeutic proteins, mammalian cell culture, bioreactors, protein folding, post-translational modification, volumetric productivity, culture medium optimization, process control, vector engineering, host cell engineering
- MeSH terms
- Animals, Cells, Cultured, Humans, Mammals, Recombinant Proteins, Transfection, Protein Engineering, Cell Culture Techniques, Bioreactors, Genetic Enhancement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.